Literature DB >> 9560765

Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.

R L Hamlin1, T Nakayama.   

Abstract

This study was designed to determine the degree of inhibition of the angiotensin-converting enzyme (ACE) in 5 normal dogs given single doses of conventionally used ACE inhibitors (ACEis). In addition the time required for that inhibition to return to 50% of the difference between maximum and zero (control values) was measured as an estimate of duration of action. The 5 ACEis (with dosages given in parentheses) were benazapril (0.5 mg/kg), captopril (2.0 mg/kg), enalapril (0.5 mg/kg), lisinopril (0.5 mg/kg), and ramipril (0.25 mg/kg). Blood samples for ACE activities were obtained before dosing and at 1.5, 3.0, 6.0, 12.0, and 24.0 hours after dosing. All ACEis except captopril decreased ACE activities to approximately 25% of control by the 1.5- to 3.0-hour sample, and ACE activities returned to 50% of the difference by the 12-hour sample. The value of AVE activity returned to normal by 24 hours for benazapril, whereas values for ACE activity remained below normal for enalapril, lisinopril, and ramipril at 24 hours. For captopril, however, ACE levels decreased to approximately 80% of control by the 1.5-hour recording, and returned to levels not different from control by the 3-hour recording. Based upon this study performed on normal dogs given a single dose, no pharmacokinetic advantage or disadvantage is apparent for any ACEi except captopril, which, at the dosage used, decreased ACE levels to a much lesser degree and shorter time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560765     DOI: 10.1111/j.1939-1676.1998.tb02101.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  3 in total

1.  Effects of fosinopril on renal function, baroreflex response and noradrenaline pressor response in conscious normotensive dogs.

Authors:  C Buranakarl; A Kijtawornrat; P Nampimoon
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

2.  A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.

Authors:  Daniel K Newhard; SeungWoo Jung; Randolph L Winter; Sue H Duran
Journal:  J Vet Intern Med       Date:  2018-08-07       Impact factor: 3.333

Review 3.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.